GAMMA Investing LLC Acquires 160,155 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

GAMMA Investing LLC lifted its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 11,580.3% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 161,538 shares of the company's stock after purchasing an additional 160,155 shares during the period. GAMMA Investing LLC owned 0.33% of Prestige Consumer Healthcare worth $13,887,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. Allspring Global Investments Holdings LLC grew its holdings in shares of Prestige Consumer Healthcare by 3.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,624,501 shares of the company's stock worth $126,274,000 after purchasing an additional 49,331 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Prestige Consumer Healthcare by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 1,348,745 shares of the company's stock valued at $105,342,000 after acquiring an additional 21,951 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC bought a new position in Prestige Consumer Healthcare in the fourth quarter valued at about $84,932,000. Invesco Ltd. boosted its holdings in Prestige Consumer Healthcare by 2.4% in the fourth quarter. Invesco Ltd. now owns 1,060,263 shares of the company's stock valued at $82,796,000 after acquiring an additional 24,392 shares during the last quarter. Finally, Congress Asset Management Co. boosted its holdings in Prestige Consumer Healthcare by 5.0% in the fourth quarter. Congress Asset Management Co. now owns 908,742 shares of the company's stock valued at $70,964,000 after acquiring an additional 43,619 shares during the last quarter. Institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Trading Up 0.6%

NYSE PBH opened at $85.11 on Friday. The firm has a market cap of $4.21 billion, a P/E ratio of 19.93, a P/E/G ratio of 2.69 and a beta of 0.45. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20. The stock's 50-day moving average is $83.53 and its 200-day moving average is $82.52. Prestige Consumer Healthcare Inc. has a one year low of $63.79 and a one year high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $1.32 EPS for the quarter, topping analysts' consensus estimates of $1.30 by $0.02. The company had revenue of $296.52 million for the quarter, compared to analyst estimates of $289.36 million. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Prestige Consumer Healthcare's revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.02 earnings per share. Sell-side analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. DA Davidson raised their price target on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a report on Friday, February 7th. Royal Bank of Canada raised Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th. Canaccord Genuity Group increased their target price on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a research note on Friday, February 7th. Wall Street Zen raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, May 17th. Finally, Oppenheimer increased their target price on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a research note on Thursday, February 13th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $93.33.

Insider Buying and Selling

In related news, SVP Mary Beth Fritz sold 1,678 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the transaction, the senior vice president now directly owns 17,157 shares in the company, valued at approximately $1,544,130. This trade represents a 8.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.60% of the stock is owned by corporate insiders.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.